In the Laboratory | Published:

Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration

Nature Biotechnology volume 14, pages 651652 (1996) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , 1993. Contamination of transplantable tumors, cell-lines and monoclonal antibodies with rodent viruses. Lab. Anim. Sci. 43: 296–300.

  2. 2.

    1993. Virological aspects of the quality control of human monoclonal antibodies, International Association of the Biological Standardization, Developments in biological standardization, S. Karger AG, Basel :233–236.

  3. 3.

    1993. Regulatory affairs and biotechnology in Europe. III. Introduction into good regulatory practice: Validation of virus removal and inactivation. Biotherapy 6: 93–102.

  4. 4.

    et al. 1993. Safe biotechnology (5). Recommendations for safe work with animal and human cell cultures concerning potential human pathogens. Appl. Microbiol. Biotechnol. 39: 141–147.

  5. 5.

    EEC Regulatory Document—Note for guidance—Validation of virus removal and inactivation procedures. 1991. Biologicals 19: 247–251.

  6. 6.

    and 1994. Encyclopedia of virology: Vol. 1–3. Academic Press, London.

  7. 7.

    et al. 1993 Removal of causative agent of Creutzfeldt-Jakob-disease (CJD) through membrane filtration method. Membrane 18: 357–362.

  8. 8.

    1982. Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144.

  9. 9.

    , , , 1991 Lehrbuch der Immunologie. Georg Thieme Verlag, Stuttgart.

  10. 10.

    and 1991 Validatable virus removal from protein solutions. Nature 351: 420–421.

  11. 11.

    , , , and 1990. Structure of cuprammonium regenerated cellulose hollow fiber (BMM hollow fiber) for virus removal. Polym. J. 22: 751–758.

  12. 12.

    , , , and 1991. Process validation for virus removal and inactivation. Reprinted from Biopharm.

  13. 13.

    et al. 1989. A novel method for removal of human immunodeficiency virus: Filtration with porous polymeric membranes. Vox Sang 56: 230–236.

  14. 14.

    et al. 1992. Combination of virus removal and inactivation for the process validation of bio-drugs. Murakami.H., Shirahata, S., Tachibana, H., Animal cell technology: Basic and applied aspects, Kluwer Academic Publishers, Dordrecht :289–294.

  15. 15.

    , , , and 1994. a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang. 67: 132–138.

  16. 16.

    et al. 1991. Elimination of microorganisms from cell culture medium using regenerated cellulose hollow fiber (BMM). Sasaki, R. & Ikura, K., Animal Cell Culture and Production of Biologicals, Kluwer Academic Publishers, Dordrecht: 87–94.

  17. 17.

    et al. 1991. Studies on virus elimination and inactivation effects of highly purified factor VIII concentrates. Jpn. Clin. Rep. 25: 1–8.

  18. 18.

    et al. 1989. Possibility of hepatitis B virus removal from human plasma using regenerated cellulose hollow fiber (BMM). Membrane 14: 77–83.

  19. 19.

    et al. 1991. The particle size of hepatitis C virus estimated by filtration through microporous regenerated cellulose fibre. J. Gen. Virolog. 72: 2021–2024.

  20. 20.

    EC note for guidance: Validation of virus removal and inactivation procedures. 1991. Pharmacol. Toxicol. 69: 144–148.

Download references

Author information

Affiliations

  1. Clinical immunology and transfusion medicine, University of Leipzig, Delitzscher Sir. 141, D-04129 Leipzig, Germany

    • Holger Maerz
    • , Sven Oliver Hahn
    • , Frank Emmrich
    •  & Uwe Marx
  2. Medical immunology, Humboldt-University/Charité, Monbijoustr. 2, D-10117 Berlin;

    • Sven Oliver Hahn
    •  & Heinz Tanzmann
  3. Medical virology, Humboldt- University/Charité, Schumannstr. 20-21, D-10099 Berlin;

    • Anke Maassen
    •  & Helga Meisel
  4. Dr. Fooke Laboratorien GmbH, Mainstr. 85, D-41469Neuss, Germany;

    • Dirk Roggenbuck
  5. Asahi Chemical Industries, The Imperial Tower 18F, 1-1 Uchisaiwaicho, 1-Chome, Chiyoda-Ku, Tokyo 100, Japan.

    • Tetsuo Sato
  6. Tel: +49 (341) 9725-452/455, fax : +49 (341) 9725-389, e-mail: hmae@server3.medizin.uni-leipzig.de and 101561.1151@compuserve.com.

    • Holger Maerz

Authors

  1. Search for Holger Maerz in:

  2. Search for Sven Oliver Hahn in:

  3. Search for Anke Maassen in:

  4. Search for Helga Meisel in:

  5. Search for Dirk Roggenbuck in:

  6. Search for Tetsuo Sato in:

  7. Search for Heinz Tanzmann in:

  8. Search for Frank Emmrich in:

  9. Search for Uwe Marx in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt0596-651

Further reading